Vistagen Therapeutics Inc (VTGN) Director Jon S. Saxe Purchases 12,080 Shares
Vistagen Therapeutics Inc (NASDAQ:VTGN) Director Jon S. Saxe purchased 12,080 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was bought at an average cost of $1.26 per share, with a total value of $15,220.80. Following the acquisition, the director now owns 3,251 shares in the company, valued at approximately $4,096.26. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ VTGN traded down $0.01 on Friday, hitting $1.27. The company had a trading volume of 495,452 shares, compared to its average volume of 272,780. The firm has a market cap of $54.55 million, a PE ratio of -1.14 and a beta of -0.34. Vistagen Therapeutics Inc has a 12-month low of $0.81 and a 12-month high of $2.44.
Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Tuesday, February 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). As a group, research analysts predict that Vistagen Therapeutics Inc will post -0.9 EPS for the current fiscal year.
Several equities research analysts recently commented on the stock. Maxim Group reissued a “buy” rating and issued a $6.00 price target on shares of Vistagen Therapeutics in a report on Wednesday, March 6th. ValuEngine lowered shares of Vistagen Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $8.30.
COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/vistagen-therapeutics-inc-vtgn-director-jon-s-saxe-purchases-12080-shares/2897232.html.
About Vistagen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Read More: What is a Candlestick Chart?
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.